Truist Financial Lowers Teleflex (NYSE:TFX) Price Target to $149.00

Teleflex (NYSE:TFX - Get Free Report) had its price target lowered by Truist Financial from $200.00 to $149.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a "hold" rating on the medical technology company's stock. Truist Financial's target price would suggest a potential upside of 10.12% from the stock's previous close.

A number of other equities research analysts also recently issued reports on TFX. Raymond James downgraded shares of Teleflex from an "outperform" rating to a "market perform" rating in a research report on Friday. Wells Fargo & Company cut their target price on shares of Teleflex from $214.00 to $146.00 and set an "equal weight" rating for the company in a research report on Friday. Citizens Jmp downgraded shares of Teleflex from an "outperform" rating to a "market perform" rating in a research report on Thursday. Royal Bank of Canada downgraded shares of Teleflex from an "outperform" rating to a "sector perform" rating and cut their target price for the stock from $220.00 to $155.00 in a research report on Friday. Finally, Piper Sandler reiterated a "neutral" rating and issued a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research report on Friday. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $188.33.

Teleflex Trading Up 1.9 %

Shares of NYSE:TFX traded up $2.56 during mid-day trading on Monday, hitting $135.31. The stock had a trading volume of 2,114,507 shares, compared to its average volume of 781,358. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The company has a market cap of $6.28 billion, a PE ratio of 26.90, a P/E/G ratio of 1.73 and a beta of 1.16. Teleflex has a 12-month low of $128.55 and a 12-month high of $249.90. The company's 50 day moving average is $174.58 and its 200-day moving average is $203.93.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating the consensus estimate of $3.86 by $0.03. The business had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. On average, sell-side analysts predict that Teleflex will post 13.98 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Avior Wealth Management LLC grew its stake in Teleflex by 190.6% in the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company's stock valued at $38,000 after buying an additional 101 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Teleflex in the 3rd quarter valued at $40,000. Headlands Technologies LLC acquired a new position in Teleflex in the 4th quarter valued at $29,000. True Wealth Design LLC grew its stake in Teleflex by 16,600.0% in the 3rd quarter. True Wealth Design LLC now owns 167 shares of the medical technology company's stock valued at $41,000 after buying an additional 166 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new position in Teleflex in the 3rd quarter valued at $54,000. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.